Cytomegalovirus IL-10 in Plasma as a Marker of Active Infection in Allogeneic Hematopoietic Transplant Recipients: An Exploratory Study
We investigated whether plasma cytomegalovirus (CMV) IL-10 (cmvIL-10) levels could serve as a biomarker of active CMV replication in allogeneic hematopoietic transplant recipients (allo-HCT) in the presence or absence of letermovir (LMV) prophylaxis. A total of 189 leftover plasma samples that teste...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Institución: | INCLIVA |
| Repositorio: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p20703 |
| Acceso en línea: | https://incliva.portalinvestigacion.com/publicaciones/20703 |
| Access Level: | acceso abierto |
| Palabra clave: | active CMV infection allogeneic hematopoietic stem cell transplantation CMV DNAemia cmvIL-10 cytomegalovirus (CMV) |
| Sumario: | We investigated whether plasma cytomegalovirus (CMV) IL-10 (cmvIL-10) levels could serve as a biomarker of active CMV replication in allogeneic hematopoietic transplant recipients (allo-HCT) in the presence or absence of letermovir (LMV) prophylaxis. A total of 189 leftover plasma samples that tested positive for CMV DNA (Alinity m CMV assay), representing 33 episodes of CMV DNAemia were run on a laboratory-developed enzyme-linked immunosorbent assay for cmvIL-10 quantification. Eighteen episodes developed during LMV prophylaxis. Overall, 16 episodes of CMV DNAemia were classified as clinically significant (CsCMVi). There was an overall very weak correlation between the two biomarkers (Rho = 0.10; p = 0.16). Overall, the median cmvIL-10 area under the curve (AUC) until CMV DNA levels reached their peak was significantly higher (p < 0.001) in CsCMVi episodes than in non-CsCMVi episodes. cmvIL-10 AUC between Days 14 and 23 after allo-HCT (AUC(1)(4)(-)(2)(3)) values were significantly higher in CsCMVi episodes compared with non-CsCMVi episodes among patients receiving LMV therapy (p = 0.008). An AUC(1)(4)(-)(2)(3) cutoff value of log(10) 3.06 discriminated anticipately between CsCMVi and non-CsCMVi with a sensitivity and specificity of 100%. Plasma cmvIL-10 levels may reflect true CMV replication and thus provide a unique perspective on viral dynamics, serving as an ancillary marker to CMV DNA monitoring. |
|---|